Analyst Reco. LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
6.79 ^USD	-2.02%		-13.72%	-18.09%

25/06	LifeMD Launching Private Health Insurance Acceptance For Primary Care Services	MT
25/06	LifeMD, Inc. Launches Commercial Health Insurance Acceptance for Its Primary Care Services, Including Weight Management	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LifeMD Launching Private Health Insurance Acceptance For Primary Care Services	25/06	MT
KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	05/06	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	09/05	MT
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	23/04	MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	12/03	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	12/03	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	12/03	MT
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	11/01	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	14/11	MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	09/11	MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	09/11	MT
Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	02/23/02	MT
Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	21/23/21	MT
B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	10/23/10	MT
HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	03/23/03	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23/23/23	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23/23/23	MT
B. Riley Lowers LifeMD's Price Target to $8 from $16, Notes Slower-than-Anticipated Start in Q1 Impacted by Technology Upgrades, Integrations; Keeps Buy Rating	16/22/16	MT
BTIG Adjusts LifeMD's Price Target to $15 From $30, Reiterates Buy Rating	11/21/11	MT
LIFEMD : BTIG Research Adjusts LifeMD Price Target to $30 From $35, Maintains Buy Rating	13/21/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. LifeMD, Inc.

Equities

LFMD

US53216B1044

Analyst Reco.

Filters